Geode Capital Management LLC Buys 51,111 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)

Geode Capital Management LLC increased its stake in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) by 12.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 448,997 shares of the company’s stock after acquiring an additional 51,111 shares during the quarter. Geode Capital Management LLC owned approximately 1.40% of Candel Therapeutics worth $3,112,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Bank of New York Mellon Corp bought a new stake in shares of Candel Therapeutics during the second quarter valued at approximately $338,000. Cubist Systematic Strategies LLC bought a new stake in Candel Therapeutics during the 2nd quarter valued at $162,000. Rhumbline Advisers acquired a new position in Candel Therapeutics during the second quarter worth $143,000. Barclays PLC raised its holdings in Candel Therapeutics by 327.1% during the third quarter. Barclays PLC now owns 28,688 shares of the company’s stock worth $199,000 after buying an additional 21,971 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Candel Therapeutics by 4.1% in the third quarter. State Street Corp now owns 492,005 shares of the company’s stock valued at $3,410,000 after buying an additional 19,207 shares in the last quarter. 13.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $19.00 target price (up previously from $11.00) on shares of Candel Therapeutics in a report on Wednesday, December 18th.

Candel Therapeutics Stock Down 5.6 %

Shares of NASDAQ:CADL opened at $8.70 on Tuesday. The business’s 50 day moving average is $6.11 and its 200 day moving average is $6.15. Candel Therapeutics, Inc. has a 12-month low of $1.16 and a 12-month high of $14.60. The stock has a market cap of $282.54 million, a price-to-earnings ratio of -5.03 and a beta of -1.20. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 1.66.

Insider Transactions at Candel Therapeutics

In other news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $6.02, for a total value of $90,300.00. Following the transaction, the insider now owns 929,873 shares in the company, valued at $5,597,835.46. The trade was a 1.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Paul B. Manning purchased 1,250,000 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were acquired at an average cost of $6.00 per share, with a total value of $7,500,000.00. Following the completion of the transaction, the director now directly owns 1,303,752 shares of the company’s stock, valued at $7,822,512. The trade was a 2,325.49 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 64,327 shares of company stock worth $337,581 in the last quarter. 41.60% of the stock is currently owned by corporate insiders.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.